ALX Oncology Holdings Inc.

ALXO · NasdaqGS

Price$0.00+0.00 (+0.00%)

Price History

Volume & Moving Averages

Price50D200D

Analyst Price Target

$0.00▲ 0.0% above current price

Range: $0.00 – $0.00 · 0 analysts

Based on Wall Street analyst estimates — not a Stockinder prediction.

About the company

Jarvis is thinking

Key Metrics

Report card

Open as standalone page ↗

Jarvis is thinking

Recent Notable Coverage

Jarvis is thinking

Report Card

–

Growth

Health

Risk

–

Value

Quality

Ownership

Insider and institutional holdings, from Yahoo Finance — for Indian companies this roughly tracks promoter (insiders) and combined FII/DII (institutions) stakes, though not split out the same way a shareholding-pattern filing would.

Insiders0.9%

Institutions84.6%

Public / Other

Income Statement

	2025-12-31	2024-12-31	2022-12-31	2021-12-31	2020-12-31
Total money the company brought in from its core business during the period, before any costs are subtracted.	–	–	$0	–	$1.18M
Profit from core operations after subtracting the cost of revenue and operating expenses like R&D and marketing, but before interest and taxes.	-$104.02M	-$142.47M	-$127.44M	-$83.56M	-$43.66M
Operating income as a percentage of revenue.	–	–	–	–	-3694.0%
The company's bottom-line profit after all expenses, interest, and taxes are subtracted.	-$101.69M	-$134.85M	-$123.48M	-$83.46M	-$45.74M
Net income divided by the number of shares outstanding — profit attributable to each share.	$-1.90	$-2.58	–	–	–
Like basic EPS, but accounts for shares that could be created from stock options or convertible securities — a more conservative per-share profit figure.	$-1.90	$-2.58	–	–	–

Balance Sheet

	2025-12-31	2024-12-31	2022-12-31	2021-12-31	2020-12-31
Cash and highly liquid short-term investments the company can access almost immediately.	$16.37M	$17.57M	$48.82M	$363.67M	$434.22M
Everything the company owns that has value — cash, property, inventory, investments, and more.	$59.05M	$147.78M	$306.49M	$380.18M	$436.05M
All of the company's interest-bearing borrowings, short and long term combined.	$9.75M	$9.90M	$9.39M	–	–
Everything the company owes — debt, unpaid bills, and other obligations.	$33.06M	$34.16M	$43.02M	$17.13M	$6.21M
What would be left for shareholders if the company sold all its assets and paid off all its debts — total assets minus total liabilities.	$25.98M	$113.62M	$263.46M	$363.05M	$429.85M

Cash Flow Statement

	2025-12-31	2024-12-31	2022-12-31	2021-12-31	2020-12-31
Actual cash generated by the core business, as opposed to accounting profit, which can include non-cash items.	-$84.14M	-$121.91M	-$89.22M	-$68.10M	-$38.29M
Cash spent on physical assets like property, equipment, and infrastructure to maintain or grow the business.	$212000	$447000	$1.43M	$666000	$31000
Cash left over after capital expenditures — money the company could use for dividends, buybacks, debt repayment, or reinvestment.	-$84.35M	-$122.36M	-$90.65M	-$68.77M	-$38.32M

	You	Peer avg
Revenue Growth	–	+335.6%
ROE	-80.6%	-225.8%

ALX Oncology Holdings Inc.

Price History

Volume & Moving Averages

Analyst Price Target

About the company

Key Metrics

Report card

Jarvis Analysis

Recent Notable Coverage

Report Card

Ownership

Quick Actions

Reports & Coverage

Con Call Reports

Board of Directors / Annual Reports

Recent Articles

Income Statement

Balance Sheet

Cash Flow Statement

Peer Comparison